Phaseline

Targets › ATP4B

ATP4B (Potassium-transporting ATPase subunit beta): drug programs, companies and trials

20 programs from 18 companies in 60 trials: 25 Phase 4, 20 Phase 2, 12 Phase 3, 3 Phase 1; Gastroenterology, Oncology, Genitourinary; next expected readout Nov 2026.

The beta subunit of the gastric H(+)/K(+) ATPase pump which transports H(+) ions in exchange for K(+) ions across the apical membrane of parietal cells. Plays a structural and regulatory role in the assembly and membrane targeting of a functionally active pump (By similarity). (UniProt, P51164)

Open in Phaseline: the race on ATP4B, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Odense University HospitalCapsule FMT
Amiloride-sensitive sodium channel, ENaC blocker
GLP1R, ATP4A, ATP4B, CTLA4, FKBP1A, TNF, PDCD1, SCNN1A, SCNN1B, SCNN1GPhase 4Gastroesophageal Reflux; Colitis; Chronic Kidney Disease(CKD); Postmenopausal Women …Dec 2026
Stephen FirkinsOmeprazole
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 4Marginal UlcerMar 2027
Prof Urs ZinggEsomeprazol MUT Sandoz® 40mg tablet
Proton pump inhibitor (PPI)
ATP4A, ATP4BPhase 4ObesityDec 2027
Dow University of Health SciencesDexlansoprazole
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 4H. Pylori Gastrointestinal Disease–
Dow University of Health SciencesLansoprazole
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 4H. Pylori Gastrointestinal Disease–
Carnot LaboratoriesTegoprazan
Potassium-transporting ATPase blocker
ATP4A, ATP4BPhase 4Gastroesophageal Reflux Disease; Helicobacter Pylori Infection Chronic Gastrit; Coronary Artery Disease; Ischemic Stroke …–
Phathom PharmaceuticalsVonoprazan
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 3Symptomatic Non-erosive Gastroesophageal Reflux Disease; Eosinophilic Esophagitis; Gastritis, Indigestion, Helicobacter Pylori Infection, Gastric Cancer, Peptic Ulcer; HELICOBACTER PYLORI INFECTIONS …Dec 2026
Il-Yang Pharm.Ilaprazole
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 3Peptic UlcerAug 2027
Ottawa Hospital Research InstituteOmeprazole
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 3Venous ThromboembolismDec 2027
Sherief Abd-ElsalamPantoprazole
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 3OncologyDec 2030
National Cancer Center, KoreaLansoprazole
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 3Gastric CancerDec 2035
AstraZenecaEsomeprazole
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 3Erosive Esophagitis; Liver Cirrhosis; Helicobacter Pylori Infections; Radiation Esophagitis …–
Norfolk and Norwich University Hospitals NHS Foundation TrustLansoprazole
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 3Idiopathic Pulmonary Fibrosis–
The University of Texas Health Science Center, HoustonPantoprazole
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 2Acute Kidney InjuryDec 2026
United States Naval Medical Center, Portsmouthpantoprazole
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 2Postoperative Nausea and VomitingDec 2026
Wake Forest University Health SciencesOmeprazole
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 2Prostate CancerFeb 2028
Universidad Autonoma de Nuevo LeonOmeprazole
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 2Morbidity–
Universidad Autonoma de Nuevo LeonPantoprazole
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 2Morbidity–
Murdoch Childrens Research InstituteOmeprazole
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 1Hodgkin LymphomaNov 2026
Caroline Sameromeprazole
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 1Healthy Volunteers–

Conditions

HELICOBACTER PYLORI INFECTIONS (5) Helicobacter Pylori Infection (4) H. Pylori Infection (4) H. Pylori Gastrointestinal Disease (3) Acute Kidney Injury (2) Morbidity (2) Obesity (2) Oncology (2) Symptomatic Non-erosive Gastroesophageal Reflux Disease (1) Eosinophilic Esophagitis (1) Gastritis, Indigestion, Helicobacter Pylori Infection, Gastric Cancer, Peptic Ulcer (1) Gastroesophageal Reflux Disease (GERD) (1)

Modalities

small molecule (18), protein or peptide (1)

Companies

Universidad Autonoma de Nuevo Leon (2) Dow University of Health Sciences (2) Phathom Pharmaceuticals (1) Il-Yang Pharm. (1) The University of Texas Health Science Center, Houston (1) Ottawa Hospital Research Institute (1) Murdoch Childrens Research Institute (1) Prof Urs Zingg (1) Sherief Abd-Elsalam (1) Wake Forest University Health Sciences (1) Stephen Firkins (1) Odense University Hospital (1) Norfolk and Norwich University Hospitals NHS Foundation Trust (1) Carnot Laboratories (1) National Cancer Center, Korea (1) United States Naval Medical Center, Portsmouth (1) Caroline Samer (1) AstraZeneca (1)

Related targets

ATP4A (20) GLP1R (1) CTLA4 (1) FKBP1A (1) TNF (1) PDCD1 (1) SCNN1A (1) SCNN1B (1) SCNN1G (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.